AstraZeneca hopes purchase breaks new-product slump: MedImmune offers access to vaccines, biological drugs

Article Abstract:

UK pharmaceutical firm AstraZeneca PLC will purchase MedImmune Inc. for $15.6 bil, a move that will give the company a stronger presence in the vaccines and biological drugs markets. The deal, expected to conclude in June, will increase AstraZeneca's proportion of biological drugs by approximately 20%.

Product development, Strategy & planning, Biological Product (except Diagnostic) Manufacturing, Drugs, Biological Products, United Kingdom, United States, Planning, Biological products industry, AstraZeneca PLC, MedImmune Inc., AZN, Company business planning

---

Two deals for Europe's drug makers

Article Abstract:

Merck KGaA of Germany is to purchase Serono S.A. of Switzerland for 10.6 billion Euros. Nycomed of Denmark is to purchase Altana AG of Germany for 4.5 billion Euros. The pharmaceutical industry acquisitions aid business viability in a very competitive market.

Denmark, Germany, Switzerland, Merck KGAA, Altana Industrie-Aktien und Anlagen AG, Merck Serono S.A., Company overview, Industry overview

---

Similar abstracts:

• Abstracts: Hollywood rewrite: Viacom outbids GE to buy DreamWorks. Walt Disney is in serious talks to acquire Pixar. DreamWorks net plunges as video sales disappoint
• Abstracts: Pepsi raises full-year profit outlook: orange costs pressed down latest results, but diversity of portfolio cushioned blow
• Abstracts: Flood of applicants holds up SA rights. Alaska cod fishery first to win eco-tag. Saithe fishery for MSC certification

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.